Hyderabad, March 02, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the antibiotics market size was valued at USD 55.60 billion in 2025 and is projected to increase from USD 57.86 billion in 2026 to USD 70.64 billion by 2031, registering a CAGR of 4.07% during the 2026–2031 forecast period. Market growth is supported by the rising incidence of bacterial infections, increasing hospital admissions, and ongoing investment in antimicrobial research and development. The growing global burden of respiratory, urinary tract, bloodstream, and hospital-acquired infections continues to sustain demand for effective antibiotic therapies, reinforcing their central role in clinical treatment practices.
The antibiotics market is expanding as pharmaceutical companies focus on developing novel drug classes and improved formulations to combat antimicrobial resistance. Rising awareness of multidrug-resistant organisms is encouraging innovation in targeted therapies and combination treatments. Additionally, improvements in rapid diagnostic testing are supporting more precise antibiotic selection, promoting responsible prescribing practices, and optimized patient outcomes.
Antibiotics Market Share by Region
Asia-Pacific is emerging as a high-growth region due to rising infection rates, expanding healthcare access, increasing awareness regarding infectious diseases, and growing pharmaceutical production capacity.
North America represents a significant share of the antibiotics market, supported by advanced healthcare infrastructure, established pharmaceutical manufacturing capabilities, and ongoing research initiatives aimed at addressing antimicrobial resistance.
Europe holds a notable position in the market, driven by structured antibiotic stewardship programs, regulatory initiatives, and strong public health frameworks focused on infection management.
Soumya Goud, Senior Research Manager, Mordor Intelligence, says, “The antibiotics market continues to reflect steady demand shaped by treatment needs, regulatory oversight, and evolving healthcare access across regions. Mordor Intelligence’s structured analysis, grounded in independently sourced data and consistent validation, offers decision-makers a transparent view beyond fragmented estimates.”
Antibiotics Market Trends & Forecast
Rising Focus on Combating Antimicrobial Resistance
Increasing prevalence of resistant bacterial strains is driving investment in research and development of novel antibiotics and combination therapies.
Expansion of Hospital and Critical Care Services
Growth in surgical procedures and intensive care admissions supports sustained demand for prophylactic and therapeutic antibiotic treatments.
Antibiotics Market Segmentation Overview
By Product Class
- Cephalosporins
- Penicillins
- Fluoroquinolones
- Macrolides
- Carbapenems
- Aminoglycosides
- Sulfonamides
- Tetracyclines
- Other Classes
By Spectrum
- Broad-Spectrum Antibiotics
- Narrow-Spectrum Antibiotics
By Route of Administration
- Oral
- Intravenous
- Intramuscular
- Topical
- Other Routes
By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: https://www.mordorintelligence.com/industry-reports/antibiotics-market?utm_source=globenewswire
Antibiotics Market Competitive Outlook
The antibiotics market features global pharmaceutical manufacturers focusing on pipeline expansion, strategic collaborations, and innovation in next-generation antimicrobial therapies. Companies are prioritizing research into resistant pathogens, strengthening manufacturing capabilities, and expanding geographic reach to address evolving infection management needs.
Antibiotics Companies include:
- Abbott Laboratories
- AstraZeneca plc
- Aurobindo Pharma Ltd.
- Bayer AG
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- Fresenius Kabi
- GSK plc
- Hikma Pharmaceuticals PLC
- Johnson & Johnson
- Lupin Limited
- Melinta Therapeutics
- Merck & Co., Inc.
- Sandoz AG
- Otsuka Pharmaceutical Co., Ltd.
- Paratek Pharmaceuticals
- Pfizer Inc.
- Sanofi
- Shionogi & Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/antibiotics-market?utm_source=globenewswire
Check out related reports published by Mordor Intelligence
Anticoagulants Market Size - The anticoagulants market is estimated at USD 37.56 billion in 2026 and is projected to reach USD 51.13 billion by 2031, registering a CAGR of 6.36% during the forecast period. Growth is driven by the rising prevalence of cardiovascular disorders, increasing incidence of thromboembolic conditions, and growing adoption of novel oral anticoagulants in long-term disease management.
Johnson & Johnson, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company and Sanofi are the major companies operating in this market.
Read more about the companies in the Anticoagulants Market: https://www.mordorintelligence.com/industry-reports/anticoagulants-market/companies?utm_source=globenewswire
Scopolamine Market Share - The scopolamine market is expected to grow from USD 492.66 million in 2026 to USD 642.28 million by 2031, at a CAGR of 5.46% over the forecast period. Market expansion is supported by increasing demand for motion sickness treatments, growing surgical procedures requiring antiemetic support, and expanding applications in nausea management.
Pfizer Inc., Baxter International Inc., Novartis AG, GlaxoSmithKline plc and Perrigo plc are the major companies operating in this market.
Read more about the companies in the Scopolamine Market: https://www.mordorintelligence.com/industry-reports/scopolamine-market/companies?utm_source=globenewswire
Antacids Market Growth - The antacids market is projected to grow from USD 7.30 billion in 2026 to USD 8.65 billion by 2031, registering a CAGR of 3.45% during the forecast period. Growth is driven by rising prevalence of gastrointestinal disorders, increasing self-medication trends, and sustained demand for over-the-counter digestive relief products.
Sanofi S.A, Bayer AG, Haleon Plc, Sun Pharmaceutical Industries Ltd. and Johnson & Johnson (Kenvue) are the major companies operating in this market.
Read more about the companies in the Antacids Market: https://www.mordorintelligence.com/industry-reports/antacids-market/companies?utm_source=globenewswire
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
